Q-omics provides the consensus-scored HTR1A profile across patient tissues and cancer cell-line models. HTR1A expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, HTR1A is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, HTR1A protein abundance shows 8,415 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, KIRC, and GBM as cancer lineages where HTR1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR1A survival associations across molecular data types. HTR1A RNA expression shows survival associations in the most cancer types (16), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR1A RNA expression–survival associations across cancer types. High HTR1A expression shows unfavorable associations in STAD, LUSC and DLBC, but favorable associations in LGG, UVM and LAML. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for HTR1A RNA expression.
This table summarizes HTR1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HTR1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR1A shows lower tumor expression in KIRC and PRAD and higher tumor expression in BRCA. The KIRC box plot shows higher HTR1A RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p = .014).
This table shows molecular features associated with HTR1A in patient tissues and cancer cell lines. In patient samples, HTR1A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
